Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Shuangdi Granule plus systemic therapy for unresectable intrahepatic cholangiocarcinoma
ChiCTR2100052035Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Compound Shuangdi in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Overall survival. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
Compound Shuangdi
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2100052035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052035.